Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19. Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) being developed to treat infected, high-risk individuals with COVID-19 Exploring the potential to repurpose marketed products
Takeda appoints new Area Head for India, C.I.S., Middle East, Turkey, and Africa. Dr.Mahender Nayak , proven leader with more than 20 years of experience in biopharmaceutical industry will continue
